MD
Pediatrix Medical Group, Inc.
MD's fundamentals are mixed, but it looks expensive: trading at 17x earnings, above its usual 13x. Analysts expect earnings growth.
MD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Healthy |
MD's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
MD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $19.61 | -38% |
| Fair | 13x | $23.57 | -25% |
| Forward | 13x | $31.40 | — |
| Current | 17x | $31.40 | — |
| Expensive | 19x | $34.33 | +9.3% |
Historical ranges are pointers, not guarantees.
MD's PE is in its expensive range at 17x. If earnings grow as analysts expect, today's price would be 13x next year's earnings, in its fair range.
MD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect MD's earnings to grow and its profitability to improve, with its revenue holding steady.
MD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.45 | +33% |
| Q3 2026 | $1.84 | -3.7% |
| Q2 2026 | $2.09 | +61% |
| Q1 2026 | $2.06 | +$3.06 |
| Q4 2025 | $1.94 | +$3.13 |
| Q3 2025 | $1.91 | +$4.97 |
| Q2 2025 | $1.30 | +$4.33 |
| Q1 2025 | -$1.00 | -$0.15 |
| Q4 2024 | -$1.19 | -$0.46 |
MD earned $1.84 per share over the past year, down 3.7% from the year before.
MD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $501.4M | +1.7% |
| Q2 2026 | $487.8M | +4% |
| Q1 2026 | $476.2M | +3.9% |
| Q4 2025 | $493.8M | -1.7% |
| Q3 2025 | $492.9M | -3.6% |
| Q2 2025 | $468.8M | -7% |
| Q1 2025 | $458.4M | -7.4% |
| Q4 2024 | $502.4M | +1.2% |
MD's revenue fell from its 2019 peak and has held roughly level since: $501M last quarter, up 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -0.8 points |
| Q2 2026 | 12% | -1.1 points |
| Q1 2026 | 8.8% | +1.8 points |
| Q4 2025 | 9.9% | +2.1 points |
| Q3 2025 | 14% | +7.2 points |
| Q2 2025 | 13% | +44 points |
| Q1 2025 | 7% | +3.8 points |
| Q4 2024 | 7.8% | +30 points |
MD's operating margin was 13% last quarter, down 0.8 points from the same quarter a year ago.
MD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $112.9M | -14% |
| Q2 2026 | $123.9M | -6.6% |
| Q1 2026 | -$136.1M | -$15.3M |
| Q4 2025 | $108.8M | -16% |
| Q3 2025 | $131.9M | +54% |
| Q2 2025 | $132.7M | +33% |
| Q1 2025 | -$120.8M | +$9.8M |
| Q4 2024 | $129.6M | +115% |
MD still generates free cash flow, though less than at its 2020 peak: $210M over the past year.
MD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -1.7M shares |
| 1 year | -6.9% | -5.9M shares |
| 3 years | -3.9% | -3.2M shares |
| 5 years | -7.4% | -6.4M shares |
| Available history | -4.3% | -3.6M shares |
MD has 80M diluted shares, down 6.9% from a year ago, with $211M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $83M |
| Q2 2026 | $42.7M |
| Q1 2026 | $21.5M |
| Q4 2025 | $64M |
| Q3 2025 | $20.9M |
| Q2 2025 | $209,000 |
| Q1 2025 | $1.6M |
| Q4 2024 | $643,000 |
MD spent $211M buying back its own shares over the past year, about nine times what it spent the year before.
MD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.6x | Healthy |
| Q4 2025 | 1.0x | Very low |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 2.0x | Moderate |
| Q1 2024 | 2.9x | Moderate |
| Q4 2023 | 12.9x | High |
MD's net debt is about 1.1 years of its operating earnings (EBITDA), about the same as a year ago.
MD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 77.7 | Overbought |
| Stochastic | 80.5 | Overbought |
MD's weekly RSI is 78 (overbought) and its Stochastic is 81 (overbought).
MD PE vs Healthcare Sector
| Metric | MD | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 72 | 29 | 43 pts above |
MD is trading at 17x earnings, a 34% discount to the Healthcare sector's median of 26x.
MD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.5 | 10% above |
| 20 week MA | $27.3 | 15% above |
| 50 week MA | $24.0 | 31% above |
| 100 week MA | $19.6 | 60% above |
| 200 week MA | $15.6 | 101% above |
MD is in an uptrend: it's above all five of its weekly moving averages, and 101% above its 200-week average.
MD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.2 | $23.9 | -12% |
| 2021 | $23.9 | $27.6 | +15% |
| 2022 | $27.6 | $14.9 | -46% |
| 2023 | $14.9 | $9.30 | -38% |
| 2024 | $9.30 | $13.5 | +45% |
| 2025 | $13.5 | $21.9 | +62% |
| 2026 YTD | $21.9 | $31.4 | +44% |
MD is up 44% so far in 2026, after finishing lower in three of the previous six years.